IL-13 alpha 2 receptor (IL13RA2) Active Protein | IL13RA2 active protein

Human IL-13 alpha 2 receptor Recombinant (IL13RA2)

Cat. Num. AAA553247

• Purity: >98%, as determined by SDS-PAGE and HPLC
• Synonyms: IL-13 alpha 2 receptor (IL13RA2); Human IL-13 alpha 2 receptor Recombinant (IL13RA2); Human IL-13 alpha 2 receptor Recombinant; IL13RA2; IL-13RA2; CD213; IL13RA2 active protein

• Host: HEk293 Cells
• Purity/Purification: >98%, as determined by SDS-PAGE and HPLC
• Form/Format: Recombinant IL-13 receptor alpha 2 is supplied as lyophilized 0.2 um filtered PBS solution, pH7.2.
• Sequence Length: 380

• Host Note: Optimized DNA sequence encoding extracellular domain of human IL-13 receptor alpha2 including an IgG1 human Fc region was expressed in HEK293 cells.
• Biological Activity: Measured by its ability to bind recombinant human Interleukin-13 at a concentration range of 0.3-8ng/ml.
• Presentation: Recombinant IL-13 receptor alpha 2 is supplied as lyophilized 0.2 um filtered 50mM Tris, 100mM glycine solution, pH 7.5 and 5% trehalose.
• Reconstitution: A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1mg/mL. It is recommended to add 0.1% HSA or BSA for long term storage.
• Endotoxin: Endotoxin content was assayed using a LAL gel clot method.; Endotoxin level was found to be less than 0.1 ng/ug (1EU/ug).
• Molecular Weight Note: Recombinant IL-13RA2 is a homodimer protein consisting of 563 amino acid residue subunits, due to glycosylation migrates as an approximately 130kDa protein on SDS-PAGE.
• Preparation and Storage: Recombinant IL13RA2, as supplied, can be stored in working aliquots at 2 degree - 8 degree C for one month, or at -20 degree C to -70 degree C for twelve months.; ; Avoid repeated freeze/thaw cycles.

Related Product Information for IL13RA2 active protein

The biological activity of IL-13 is regulated via the IL-13R type I and type II. The type I receptor is a heterodimer of the IL-4R α chain (IL-4Rα) and IL-13Rα1, and ligand-receptor interactions induce phosphorylation of the IL- 4Rα and subsequent activation of the signal transducers and activators of transcription (STAT) -6 signaling pathway. This pathway appears to be the primary pathway for IL-13- induced signaling in nonhematopoietic cells. The type II receptor is composed of IL-13Rα1 and IL-13Rα2. IL-13Rα2 binds IL-13 with high affinity and is proposed to act as a decoy receptor that limits the activity of IL-13. Consistent with this, mice deficient in IL-13Rα2 demonstrate exaggerated IL- 13-induced pathologies. IL- 13Rα2 possesses a short cytoplasmic tail and is without signal motifs; however, there have been a number of reports to suggest IL-13 signals through this chain, possibly via a STAT6- independent, AP-1-dependent manner to induce activation of the Tgfβ1 promoter via the IL-13 type II receptor.

Product Categories/Family for IL13RA2 active protein

Receptors CD

References

• IL-13R2 has a protective role in a mouse model of cutaneous inflammation .J. Immunol., Dec 2010; 185: 6802 - 6808.
• IL-13R2 membrane and soluble isoforms differ in humans and mice .J. Immunol., Dec 2009; 183: 7870 - 7876.
• tuning sensitivity to il-4 and il-13: differential expression of il-4r, IL-13R1, and c regulates relative cytokine sensitivity .J. Exp. Med., Oct 2008; 205: 2595 - 2608.
• novel role of il-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model .J. Immunol., Oct 2008; 181: 4656 - 4665.
• targeting IL-13R2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated pseudomonas exotoxin .Mol. Cancer Ther., Jun 2008; 7: 1579 - 1587.